P. Blaker

发表

The pharmacogenetic basis of individual variation in thiopurine metabolism.

J. Sanderson, P. Blaker, M. Arenas-Hernandez, 2012, Personalized medicine.

Is there a role for thioguanine therapy in IBD in 2017 and beyond?

K. Taylor, M. Sparrow, P. Blaker, 2017, Expert review of gastroenterology & hepatology.

A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis

C. Selinger, B. Hayee, J. Limdi, 2021, GastroHep.

Getting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyond.

J. Sanderson, P. Blaker, M. Arenas-Hernandez, 2015, Biomarkers in medicine.

A practical guide to the use of thiopurines in oral medicine.

J. Sanderson, M. Escudier, P. Blaker, 2015, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

Optimizing the use of thiopurines in inflammatory bowel disease

J. Sanderson, A. Mentzer, P. Blaker, 2015, Therapeutic advances in chronic disease.

OC-015 The Influence of Gender and Haemoglobin on TPMT Activity

J. Sanderson, V. Kariyawasam, P. Blaker, 2013, Gut.

Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease

J. Sanderson, P. Irving, V. Kariyawasam, 2017, Inflammatory bowel diseases.

Thioguanine in inflammatory bowel disease: Long-term efficacy and safety

J. Sanderson, P. Irving, T. Elliott, 2017, United European gastroenterology journal.

Detection of bowel cancer in kidney transplant recipients

D. Goldsmith, P. Blaker, 2012, BMJ : British Medical Journal.

Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.

J. Sanderson, S. Anderson, P. Irving, 2012, Journal of Crohn's & colitis.

Management of acute severe ulcerative colitis (NICE CG 166).

P. Blaker, L. Macken, 2015, Clinical medicine.

Blockers of sodium and calcium entry protect axons from nitric oxide‐mediated degeneration

Kenneth J. Smith, R. Kapoor, M. Davies, 2003, Annals of neurology.

Abdominal hereditary angio-oedema caught on magnetic resonance imaging

Rohit R. Ghurye, P. Blaker, Mayven Tien Li Siow, 2021, BMJ Case Reports.

The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic

J. Sanderson, P. Irving, J. Sanderson, 2013, International journal of clinical practice.

Let's get personal: predicting thiopurine and fluoropyrimidine toxicity.

J. Sanderson, P. Blaker, M. Arenas-Hernandez, 2012, Personalized medicine.

Physiology and function of the small intestine

P. Irving, P. Blaker, 2014 .

A search for novel biomarkers predicting toxicity and response to thiopurine treatment in patients with inflammatory bowel disease

P. Blaker, 2014 .

Mechanism of allopurinol induced TPMT inhibition.

J. Sanderson, P. Irving, L. Fairbanks, 2013, Biochemical pharmacology.

A Biochemical Mechanism for the Role of Allopurinol in TPMT Inhibition

J. Sanderson, P. Irving, L. Fairbanks, 2011 .

343 Azathioprine Decreases the Risk of Adalimumab Primary Non-Response and Secondary Loss of Response but Only if Adequately Dosed

J. Sanderson, S. Anderson, P. Irving, 2014 .

PTU-007 A retrospective multicentre study comparing infliximab and adalimumab for maintenance of remission in ulcerative colitis

C. Selinger, B. Hayee, J. Limdi, 2018, IBD.

PWE-006 The Effects of Smoking on Thiopurine Metabolism

P. Blaker, M. Arenas-Hernandez, A. Marinaki, 2016 .

Mechanism of allopurinol induced TPMT inhibition.

P. Irving, J. Sanderson, L. Fairbanks, 2013, Biochemical pharmacology.